摘要
目的:观察经过安罗替尼治疗的不同瘤种恶性肿瘤患者的相关指标,探索影响安罗替尼临床疗效和预后的因素。方法:2018年7月至2019年12月使用安罗替尼治疗的晚期恶性肿瘤患者101例,取患者治疗过程中的血液,用ELISA法和实时荧光定量PCR法检测血清中VEGF、FGF、c-Kit、Bcl-2、PARP蛋白含量和mRNA相对表达量。另一方面,评价安罗替尼的疗效和随访观察PFS。结果:全部病例的总的中位PFS为4.8月(95%CI:3.8~5.8),PR 18例(17.82%),SD 61例(60.40%),PD 22例(21.78%),ORR 17.82%,DCR 78.22%。TSH升高患者的DCR较未发生者高(P=0.0390)。既往曾使用铂类化疗者较未使用者具有更长的中位PFS(5.3月vs 3.6月,Log-rank P=0.0380),TSH升高患者较未升高患者的中位PFS显著延长(6.4月vs 4.0月,Log-rank P=0.0460),发生手足综合征者中位PFS较未发生者显著延长(11.4月vs 4.2月,Log-rank P=0.0210)。血清bFGF的蛋白含量(P=0.0090)及Bcl-2 mRNA相对表达量(P=0.0120)是安罗替尼治疗晚期恶性肿瘤预后的独立影响因子。结论:血清bFGF含量及Bcl-2 mRNA表达量是安罗替尼疗效的独立影响因素;既往曾使用铂类、发生手足综合征和促甲状腺素升高者具有更长的PFS。
Objective:To observe the relative indexes of patients with different types of malignant tumors treated with anlotinib and to explore the factors affecting the clinical efficacy and prognosis of anlotinib.Methods:From July,2018 to December,2019,101 patients with advanced malignant tumors were treated with anlotinib.The blood of the patients during the treatment was collected,and the serum levels of VEGF,FGF,c-Kit,Bcl-2,PARP and relative mRNA expression were detected by ELISA and real-time quantitative PCR.On the other hand,the efficacy of anlotinib were evaluated,and PFS was observed.Results:The median total PFS was 4.8 months(95%CI:3.8~5.8).There were 18 cases of PR(17.82%),61 cases of SD(60.40%),22 cases of PD(21.78%).ORR was 17.82%,and DCR was 78.22%.Patients with elevated TSH had higher DCR than those without elevated TSH(P=0.0390).Patients with previous platinum chemotherapy had a longer median PFS(5.3 months vs 3.6 months,Log-rank P=0.0380).The median PFS of patients with elevated TSH was significantly longer than that of patients without elevated TSH(6.4 months vs 4.0 months,Log-rank P=0.0460),and the median PFS of patients with hand-foot syndrome was significantly longer than that of patients without elevated TSH(11.4 months vs 4.2 months,Log-rank P=0.0210).The protein content of serum bFGF(P=0.0090)and the relative expression of Bcl-2 mRNA(P=0.0120)were independent influencing factors for the prognosis of advanced malignant tumors treated with anlotinib.Conclusion:The content of serum bFGF and the expression of Bcl-2 mRNA were independent factors influencing the efficacy of anlotinib.Patients with previous use of platinum,hand-foot syndrome and elevated thyrotropin had longer PFS.
作者
卢美君
赵燕仪
康马飞
LU Meijun;ZHAO Yanyi;KANG Mafei(Department of Medical Oncology,the Affiliated Hospital of Guilin Medical University,Guangxi Guilin 541001,China)
出处
《现代肿瘤医学》
CAS
北大核心
2022年第10期1831-1835,共5页
Journal of Modern Oncology
关键词
晚期恶性肿瘤
安罗替尼
治疗
抗血管生成
advanced malignant tumor
anlotinib
treatment
anti-angiogenesis
作者简介
卢美君(1991—),女,广西来宾人,硕士研究生,主要从事肿瘤药物治疗研究,E-mail:524284122@qq.com;通讯作者:康马飞(1964—),男,广西桂林人,主任医师,硕士研究生导师,主要从事肿瘤药物治疗研究,E-mail:kmfgl@163.com。
